Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6

– Topline data readout from HuMAIN trial planned for mid-2024 – – Company presenting at 2024 J.P. Morgan Healthcare Conference on January 8 at 10 a.m. PT – CHARLOTTESVILLE, Va, and SAN FRANCISCO, Jan. 5, 2024 /PRNewswire/ — Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical…

Click here to view original post

Advertisement — Advertise with Biotech Networks